Alpha Blue Ocean (“ABO”) Announces CAD 10 Million Financing Agreement with Tetra Bio-Pharma (“TBP” or the “Company”) | Company

[ad_1]

NASSAU, Bahamas–(BUSINESS WIRE)–Sept. 14, 2022–

ABO, a family office founded by Pierre Vannineuse and a pioneer in alternative finance worldwide, is proud to support the growth initiatives of Tetra Bio-Pharma with the recent financing agreement of up to CAD 10 million in convertible debentures.

The ABO financing facility, which can be used at Tetra Bio-Pharma’s discretion, enables the Company to finance the manufacturing costs of its drug candidate QIXLEEF.

Tetra is a leader in the discovery and development of cannabinoid-derived drugs with an FDA and Health Canada approved clinical program aimed at bringing new prescription drugs and treatments to patients and their healthcare providers.

Amine Nedjai, CEO of Alpha Blue Ocean

“We are delighted to partner with Tetra, a leader in cannabinoid drug discovery and development. This financing agreement, ABO’s first on the Toronto Stock Exchange, will provide funds to the Tetra team to accelerate its drug development pipeline.

Guy Chamberland, CEO of Tetra Bio-Pharma

“The Company is pleased to announce our funding agreement with Alpha Blue Ocean. This agreement provides us with capital to fund our operations and pursue the development of our drug candidates.”

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220914005427/en/

CONTACT: Rajae Elantari

[email protected]

KEYWORD: CARIBBEAN BAHAMAS NORTH AMERICA CANADA

INDUSTRY KEYWORD: BIOTECHNOLOGY FINANCE HEALTH PROFESSIONAL SERVICES PHARMACEUTICAL

SOURCE: Alpha Blue Ocean

Copyright BusinessWire 2022.

PUBLISHED: 09/14/2022 08:00/DISC: 09/14/2022 08:03

http://www.businesswire.com/news/home/20220914005427/en

Copyright BusinessWire 2022.

[ad_2]
Source link